| Total n = 2.050 | RA n = 1.228 | UA n = 127 | PsA n = 398 | SpA n = 297 |
---|---|---|---|---|---|
Age, mean (SD), years | 57.8 (14.9) | 61.4 (14.5) | 57.8 (17.1) | 54.6 (12.6) | 47.5 (12.7) |
Female gender, n (%) | 1.354 (66) | 943 (76.8) | 91 (71.7) | 196 (49.2) | 124 (41.8) |
Current smokers, n (%) | 276 (16.5) | 147 (14.6) | 23 (19.3) | 57 (18.3) | 49 (20.7) |
BMI, mean (SD) | 25.2 (5.1) | 25.0 (5.1) | 25.7 (4.8) | 26 (5.9) | 24.8 (4.1) |
 Overweight, n (%) | 525 (32.5) | 304 (31) | 39 (31.5) | 102 (35.3) | 80 (36) |
 Obese, n (%) | 233 (14.4) | 130 (13.3) | 25 (20.2) | 58 (20.1) | 20 (9) |
Hypertension, n (%) | 643 (32.5) | 430 (36.2) | 45 (35.7) | 113 (29.8) | 55 (19.2) |
Diabetes, n (%) | 158 (8) | 109 (9.2) | 6 (4.8) | 31 (8.2) | 12 (4.2) |
Disease duration, median (IQR), years | 10 (5–16) | 10 (5.9–18) | 3.8 (2–6) | 10 (5–15) | 10 (5–16) |
Use of PDN, n (%) | 641 (31.3) | 511 (41.6) | 29 (22.8) | 70 (17.6) | 31 (10.4) |
PDN dose, mean (SD), mg/day | 4.3 (3.3) | 4.3 (3.1) | 3.3 (2.2) | 4.9 (4.2) | 4.7 (4.5) |
 < 2.5 mg/day, n (%) | 57 (8.9) | 45 (8.8) | 5 (17.2) | 5 (7.1) | 2 (6.5) |
 2.5–5 mg/day, n (%) | 522 (81.4) | 417 (81.6) | 23 (79.4) | 55 (78.6) | 27 (87) |
 > 5 mg/day, n (%) | 62 (9.7) | 49 (9.6) | 1 (3.4) | 10 (14.3) | 2 (6.5) |
Use of HCQ, n (%) | 382 (18.6) | 284 (23.1) | 72 (56.7) | 21 (5.3) | 5 (1.7) |
Use of csDMARDs, n (%) | 1.048 (51.2) | 733 (59.7) | 24 (19) | 217 (54.5) | 74 (24.9) |
 MTX, n (%) | 889 (43.4) | 649 (52.9) | 17 (13.5) | 175 (44) | 48 (16.2) |
 SSZ, n (%) | 98 (4.8) | 32 (2.6) | 7 (5.6) | 35 (8.8) | 24 (8.1) |
 LFN, n (%) | 53 (2.6) | 45 (3.7) | 0 (0) | 6 (1.5) | 2 (0.7) |
 Others, n (%) | 27 (1.3) | 16 (1.3) | 0 (0) | 9 (2.3) | 2 (0.7] |
Use of b/tsDMARDs, n (%) | 1.278 (62.3) | 735 (59.9) | 0 (0) | 291 (73.1) | 252 (84.8) |
 TNF antagonists | 743 (36.2) | 339 (27.6) |  | 186 (46.7) | 218 (73.4) |
 IL6-R antagonists | 136 (6.6) | 136 (11.1) |  | 0 (0) | 0 (0) |
 IL17-IL23 antagonists | 95 (4.6) | 1 (0.08) |  | 63 (15.8) | 31 (10.4) |
 CTLA4 Ig | 146 (7.1) | 145 (11.8) |  | 1 (0.3) | 0 (0) |
 Rituximab | 14 (0.7) | 14 (1.1) |  | 0 (0) | 0 (0) |
 JAK inhibitors | 93 (4.5) | 91 (7.4) |  | 1 (0.3) | 1 (0.3) |
 IL1-R antagonists | 8 (0.4) | 8 (0.7) |  | 0 (0) | 0 (0) |
 Others | 43 (2.1) | 1 (0.08) |  | 40 (10.1) | 2 (0.7) |